Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

) where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). He currently serves on the Board of Directors for several life sciences companies including Inhibitex, Inc. and Targacept, Inc.

Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Shire HGT Collaboration

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders: Amigal, Plicera and AT2220. Under the terms of the collaboration, Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay tiered, double-digit royalties on net sales of the products. Shire also reimburses worldwide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended June 30, 2009, was $13.6 million as compared to $9.3 million for the same period in 2008. On a non-GAAP basis, the net loss for the three months ended June 30, 2009, was $11
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces ... comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact ... chemically resistant and maintenance-free solution for a broad range of vacuum filtration applications. ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... ... 31, 2015 , ... Global Resorcinol Market 2015-2019 is a ... the global resorcinol industry. The report highlights the various growth prospects and the ... analysis of primary and secondary inputs from the existing players of the resorcinol ...
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Research conducted at The,Walter and Eliza Hall ... licensing agreement signed between Australian biotechnology company,Bionomics, ... Under the Development and Licensing Agreement, Merck ... multiple sclerosis (MS) and other autoimmune,conditions. These ...
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today announced ... Vice President,of Human Resources., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Mr. Zhu worked as Head of Asia Human,Resources ...
... Antonio (June 30, 2008) Researchers at The University of ... Infectious Diseases and The University of Texas Health Science Center ... to play a role in controlling the early infectious process ... agent that is the cause of tularemia. The findings will ...
Cached Biology Technology:MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR 2UTSA/UTHSCSA publish results on bio-threat agent 2
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... poisonous frog was recently discovered in a remote mountainous ... supported by the Conservation Leadership Programme (CLP). The new ... given the name the ?golden frog of Supat. ... to several other common species in the area. However, ...
... of highly organized epithelial cells line all the cavities ... the movement of liquids,and cells in the body organs. ... serve as a barrier against cancer, according to a,study ... week in,the online edition of the Proceedings of the ...
... today by the Health Department shed new light on the ... who responded to the World Trade Center disaster on September ... Health Registry, show that 3.6% of the 25,000 rescue and ... working at the site. That rate is 12 times what ...
Cached Biology News:Cells united against cancer 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 3